Trump plans a hefty tax on imported drugs, risking higher prices and shortages

President Trump plans to impose substantial tariffs, potentially up to 200%, on imported pharmaceuticals, a sector largely exempt until now. While framed as a move to lower drug costs and reshore manufacturing, analysts predict this policy will significantly raise U.S. drug prices, potentially by 10-14% even with a 25% levy, and disrupt complex supply chains, leading to shortages, especially for low-margin generic drugs which comprise 92% of prescriptions. Despite a proposed 1-1.5 year delay and existing stockpiles, the initiative reflects a strategic shift towards national security in drug supply, prompting major drugmakers to invest in U.S. expansion, though full domestic supply chain development faces considerable cost and logistical hurdles.

Analysis

The proposal to levy substantial tariffs, potentially as high as 200%, on imported pharmaceuticals marks a significant departure from decades of duty-free policy, introducing considerable uncertainty and risk into the healthcare sector. While the stated aim is to reduce U.S. drug costs and reshore manufacturing, analysis suggests a contrary outcome. Financial economists, such as Diederik Stadig from ING, project that even a more moderate 25% tariff could inflate U.S. drug prices by 10-14% once stockpiles are depleted, disproportionately affecting consumers. A key bifurcation is emerging within the industry: brand-name manufacturers like Johnson & Johnson (J&J) and Roche are leveraging strong profit margins to make substantial investments in U.S. operations—$55 billion and $50 billion respectively—positioning themselves to mitigate tariff impacts. J&J's CEO has explicitly stated an aim to supply the U.S. market entirely from domestic sites. In contrast, the low-margin generic drug sector, which accounts for a commanding 92% of U.S. prescriptions, is highly vulnerable and may see manufacturers exit the market, risking critical shortages. Although a proposed delay of one to one-and-a-half years and existing company stockpiles of 6-18 months may defer the direct impact until 2027-2028, the strategic direction is clear. However, building a completely domestic supply chain remains a formidable challenge, as 97% of antibiotics and 92% of antivirals rely on at least one foreign-sourced active ingredient.

Key Decisions for Investors

• Investors should differentiate between pharmaceutical holdings, recognizing that manufacturers of low-margin generic drugs face significant risk of margin compression and potential market exit, while well-capitalized brand-name companies with proactive U.S. manufacturing investments, like Johnson & Johnson, may be better insulated.
• Monitor policy developments closely, as the final tariff rate and the inclusion of any exemptions for critical or generic drugs will be pivotal in determining the long-term impact on sector profitability.
• Consider the secondary impacts on the healthcare value chain, as significant drug price inflation could pressure health insurers, pharmacy benefit managers, and retail pharmacies.
• Evaluate companies based on the resilience of their supply chains, prioritizing those with significant domestic production of both finished drugs and their active pharmaceutical ingredients (APIs) to mitigate exposure to import taxes.